Westgeest, Hans M.

Amphia Ziekenhuis

1 paper on CoChatORCID 0000-0002-5735-3638

Most cited papers

Verified
Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.
Motzer, R. J., Park, S. H., McDermott, R. S., Porta, C., Heng, D. Y. C., Burotto, M., Iacovelli, R., Verzoni, E., Cutuli, H., Haanen, J., et al. (2026) · Journal of Clinical Oncology
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 9

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free